Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Immatics N.V.
IMTX
$10.89
Name : Immatics N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,460,311,808.00
EPSttm : -1.89
finviz dynamic chart for IMTX
Immatics N.V.
$10.90
0.23%
$0.025
IMTX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

4.79

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

-0.12

EPS Last/This Y

0.12

EPS This/Next Y

-0.02

Price

10.85

Target Price

18.69

Analyst Recom

1

Performance Q

18.54

Upside

-317.7%

Beta

1.33

Ticker: IMTX



15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-17IMTX9.852.780.001381
2026-03-18IMTX9.722.71999.991391
2026-03-20IMTX9.462.6933.331407
2026-03-25IMTX9.720.820.10667
2026-03-26IMTX9.760.820.10667
2026-03-27IMTX9.380.6711.00776
2026-03-30IMTX9.310.6711.00776
2026-03-31IMTX9.820.690.00787
2026-04-01IMTX10.020.670.00795
2026-04-06IMTX10.30.630.01826
2026-04-07IMTX10.270.490.00977
2026-04-08IMTX10.570.420.001089
2026-04-09IMTX10.650.400.001130
2026-04-10IMTX10.430.400.011130
2026-04-13IMTX10.860.380.001210
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-17IMTX9.85-19.3- -1.68
2026-03-18IMTX9.72-19.3- -1.68
2026-03-19IMTX9.70-19.3- -1.74
2026-03-20IMTX9.47-18.7- -1.74
2026-03-23IMTX9.52-18.7- -1.74
2026-03-24IMTX9.19-18.7- -1.74
2026-03-25IMTX9.73-18.7- -1.74
2026-03-26IMTX9.77-18.7- -1.74
2026-03-27IMTX9.37-18.7- -1.74
2026-03-30IMTX9.33-18.7- -1.74
2026-03-31IMTX9.82-18.7- -1.74
2026-04-01IMTX10.01-18.7- -1.74
2026-04-02IMTX10.38-18.7- -1.74
2026-04-06IMTX10.32-18.7- -1.74
2026-04-07IMTX10.26-18.7- -1.74
2026-04-08IMTX10.53-18.7- -1.74
2026-04-09IMTX10.68-18.7- -1.74
2026-04-10IMTX10.43-18.7- -1.74
2026-04-13IMTX10.85-18.7- -1.74
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-18IMTX0.007.994.79
2026-03-19IMTX0.007.994.79
2026-03-20IMTX0.007.994.79
2026-03-23IMTX0.007.994.79
2026-03-24IMTX0.007.994.79
2026-03-25IMTX0.007.994.71
2026-03-26IMTX0.007.994.71
2026-03-27IMTX0.007.994.71
2026-03-30IMTX0.007.594.71
2026-03-31IMTX0.007.594.71
2026-04-01IMTX0.007.594.71
2026-04-02IMTX0.007.594.71
2026-04-06IMTX0.007.594.71
2026-04-07IMTX0.007.594.71
2026-04-08IMTX0.007.594.71
2026-04-09IMTX0.007.594.71
2026-04-10IMTX0.007.594.71
2026-04-13IMTX0.007.544.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS​

-0.34

Avg. EPS Est. Current Quarter

-0.44

Avg. EPS Est. Next Quarter

-0.46

Insider Transactions

Institutional Transactions

7.54

Beta

1.33

Average Sales Estimate Current Quarter

11

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

29

Growth Score

32

Sentiment Score

66

Actual DrawDown %

33.4

Max Drawdown 5-Year %

-77.4

Target Price

18.69

P/E

Forward P/E

PEG

P/S

26.99

P/B

2.56

P/Free Cash Flow

EPS

-1.82

Average EPS Est. Cur. Y​

-1.74

EPS Next Y. (Est.)

-1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-411.76

Relative Volume

0.69

Return on Equity vs Sector %

-67.9

Return on Equity vs Industry %

-51.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

◆ IMTX Healthcare
$10.87
📉
Swing / Pullback
Buy the dip on strong trends
55 /100
WATCH
Trend
20/20
Pullback
6/25
Volume
9/15
Valuation
9/20
TP/AR
4/10
Options
7/10
RSI
62.5
Range 1M
98.9%
Sup Dist
5.4%
🚀
Momentum Growth
Ride accelerating trends
47 /100
WEAK
Momentum
19/25
Growth
10/30
Estimates
2/20
Inst/Vol
8/15
Options
8/10
EPS Yr
5.3%
EPS NY
0.8%
52W%
81.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +71.9% upside
Quality
2/30
Valuation
12/30
Growth
6/25
Stability
8/10
LT Trend
4/5
Upside
+71.9%
Quality
29
Click a card to see score breakdown Full Analysis →
Immatics N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 589
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX

Latest News

—
Caricamento notizie per IMTX…
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading